Ixazomib 2.5 mg
C16009
Phase 1 small_molecule completed
Quick answer
Ixazomib 2.5 mg for Nonhematologic Malignancies is a Phase 1 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Nonhematologic Malignancies
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed